Oral Vancomycin ( DrugBank: Vancomycin )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
94	Primary sclerosing cholangitis	5
296	Biliary atresia	1

94. Primary sclerosing cholangitis

---

Clinical trials : 148 /  Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05376228 (ClinicalTrials.gov)	February 1, 2022	11/5/2022	A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD	A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD	Inflammatory Bowel Diseases;Primary Sclerosing Cholangitis	Drug: Oral Vancomycin	University Hospital Birmingham NHS Foundation Trust	NULL	Recruiting	18 Years	N/A	All	15		United Kingdom
2	NCT03046901 (ClinicalTrials.gov)	December 7, 2016	31/1/2017	Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients	Oral Vancomycin Treatment in Recurrent Primary Sclerosing Cholangitis in Liver Transplant Recipients	Primary Sclerosing Cholangitis;Post- Orthotopic Liver Transplantation	Drug: Vancomycin	Ochsner Health System	NULL	Withdrawn	N/A	N/A	All	0	N/A	United States
3	NCT02605213 (ClinicalTrials.gov)	September 2015	31/10/2015	Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients	Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis.	Primary Sclerosing Cholangitis	Drug: Vancomycin;Drug: Placebo	Tehran University of Medical Sciences	NULL	Recruiting	18 Years	60 Years	Both	30	Phase 4	Iran, Islamic Republic of
4	NCT01802073 (ClinicalTrials.gov)	January 2012	21/2/2013	Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects	Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects	Primary Sclerosing Cholangitis	Drug: Oral Vancomycin	Stanford University	NULL	Completed	1 Year	N/A	All	34	Phase 3	United States
5	NCT02137668 (ClinicalTrials.gov)	July 2010	12/5/2014	Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin	The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin	Primary Sclerosing Cholangitis;Biliary Atresia	Drug: Oral Vancomycin	Sacramento Pediatric Gastroenterology	NULL	Recruiting	N/A	40 Years	Both	200	Phase 1	United States

Back to top

296. Biliary atresia

---

Clinical trials : 71 /  Drugs : 70 - (DrugBank : 39) / Drug target genes : 35 - Drug target pathways : 60

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02137668 (ClinicalTrials.gov)	July 2010	12/5/2014	Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin	The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin	Primary Sclerosing Cholangitis;Biliary Atresia	Drug: Oral Vancomycin	Sacramento Pediatric Gastroenterology	NULL	Recruiting	N/A	40 Years	Both	200	Phase 1	United States

Back to top